MarketCap
Johnson & Johnson JNJ
€ 236.67
1.17%
Facebook
X
Telegram
Johnson & Johnson Betriebsaufwand | JNJ
Betriebsaufwand Jährlich Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 37.3 B | 36.6 B | 30.4 B | 29.4 B | - | 31 B | 34.2 B | 32.4 B | 25.8 B | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 37.3 B | 25.8 B | 32.1 B |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
14.7 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Synthetic Biologics
SYN
|
24.1 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
137 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Qilian International Holding Group Limited
QLI
|
2.16 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
17.1 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
170 M | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
249 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
4.16 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
122 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | Germany |
 |
Codexis
CDXS
|
31.5 M | $ 1.46 | 2.82 % | $ 127 M | USA |
 |
Ardelyx
ARDX
|
95.9 M | $ 3.78 | 1.89 % | $ 911 M | USA |
 |
Affimed N.V.
AFMD
|
54 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 23.9 | 1.01 % | $ 3.04 B | USA |
 |
Assembly Biosciences
ASMB
|
84.4 M | $ 36.6 | 1.3 % | $ 410 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
106 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
7.8 M | $ 7.12 | 6.91 % | $ 4.76 M | USA |
 |
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
214 M | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 206.68 | 0.16 % | $ 10.3 B | USA |
 |
GlycoMimetics
GLYC
|
163 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
187 M | $ 56.8 | 0.94 % | $ 1.63 B | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
84 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 66.53 | 0.15 % | $ 12.8 B | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Bicycle Therapeutics plc
BCYC
|
320 M | $ 4.3 | 1.42 % | $ 298 M | Britain |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
ChromaDex Corporation
CDXC
|
66.9 M | - | -0.88 % | $ 598 M | USA |